Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a pioneering molecular diagnostics firm, proudly introduce the Bio-Marker Pathfinder (BMP), a groundbreaking ocular biomarker kit designed for point-of-care application. Novomol-Dx specializes in commercializing tests for diagnosing and treating ophthalmic diseases, leveraging biomarkers discovered in collaboration with Narayana Nethralaya Foundation and Grow Laboratories, in association with Narayana Nethralaya, a specialized eye care hospital chain based in Bangalore, India.
The BMP kit operates seamlessly on Bio-Techne’s Ella™, a sophisticated benchtop automated immunoassay platform that utilizes Bio-Techne’s R&D Systems branded reagents. It delivers precise, reliable, and highly reproducible results in less than 90 minutes. Ella’s microfluidic-based cartridges, featuring separate channels, facilitate accurate multiplexing in a hands-free system, making it exceptionally suitable for clinical diagnostic use. Novomol-Dx has developed normative data, disease-associated data, and AI-based predictive algorithms for ocular surface and retinal conditions through a proprietary algorithm. The comprehensive solution is branded as BioM-Pathfinder. The BMP kit’s novel applications encompass Dry Eye Disease, Diabetic Retinopathy, and patient stratification or monitoring related to ocular surgeries and treatments.
Dr. Rohit Shetty, Chairman at Narayana Nethralaya, remarked, “The BMP kit’s capability to generate clinically actionable data from tear samples marks a paradigm shift in diagnosing these conditions. This kit addresses a significant unmet need, given an estimated 15 million individuals suffering from various ophthalmic diseases in India. Beyond ocular applications, we anticipate the underlying technology to have potential relevance for disease-associated diagnostics or prognostics in the future.”
Dr. Naren Shetty, Vice-Chairman of Narayana Nethralaya, emphasized, “There is a pressing need for enhanced ocular diagnostic tools, and the BMP kit will expedite accurate diagnostic solutions for the millions affected by ophthalmic diseases.”
Will Geist, President of Bio-Techne’s Protein Sciences Segment, expressed optimism: “The BMP multi-analyte kit holds significant promise for Ella’s potential use in proteomic diagnostic applications. We are delighted to collaborate with this leading ocular biomarker research group and eye care institute to deliver a much-needed diagnostic tool for patients affected by these diseases.”
Dr. Arkasubhra Ghosh, Director of GROW research labs at Narayana Nethralaya Foundation, added, “We are thrilled to translate years of biomarker research in eye diseases into an application that can benefit clinicians and patients. The multi-biomarker diagnostic design establishes a platform for future expansion to broader disease applications across ophthalmic conditions, potentially including a non-invasive tear-based diagnosis for systemic conditions.”
About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company offering innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne’s products facilitate scientific investigations into biological processes, disease nature, and progression, aid drug discovery efforts, and enable accurate clinical tests and diagnoses. With a vast portfolio of thousands of products, Bio-Techne recorded over $1.1 billion in net sales in fiscal 2023 and employs approximately 3,100 professionals worldwide. For more information, visit http://www.bio-techne.com or follow the company on social media platforms like Facebook, LinkedIn, Twitter, or YouTube.
About Novomol-Dx Novomol-Dx is a collaborative startup initiative of Narayana Nethralaya Foundation, aimed at bringing solutions researched at their Grow Laboratories to local Indian and international markets. Narayana Nethralaya group of hospitals is renowned for providing quality care in India. Novomol-Dx comprises a team of seasoned professionals with extensive experience in the field, dedicated to delivering impactful solutions.
